Minoryx Therapeutics receives European Orphan Drug Designation for its lead candidate MIN-102

Minoryx Therapeutics, today announces that its lead compound MIN-102 has been granted Orphan Drug Designation by the European Medicines Agency (EMA).

TiGenix announces launch of proposed initial public offering in the United States

TiGenix NV announced today that it intends to offer and sell, subject to market and other conditions, 2.75 million American Depositary Shares (“ADSs”) representing 55 million ordinary shares in an initial public offering in the United States (the "Offering").

OxThera raises EUR 32 million to complete development of Oxabact® for treatment of Primary hyperoxaluria

OxThera AB, announces today that it has agreed on a EURO 32 million investment to complete the Oxabact® development program for treatment of Primary hyperoxaluria.

CorWave Raises $17.1 Million in Series B Financing

CorWave, has announced that it has completed a $17.1 million (€15.5M) Series B financing.

Sanifit Announces Initiation of First Clinical Trial of SNF472 in Patients with Calciphylaxis

The recently initiated Phase II study is the first clinical investigation of SNF472 in patients with newly diagnosed calciphylaxis.

Ysios Capital raises €126,4 m ($140 m) for its second fund, Ysios Biofund II Innvierte

Ysios Capital has closed its second fund, Ysios BioFund II Innvierte, at €126,4 M exceeding its initial target fund size of €100 M.

CVRx® Names Tom Moore Vice President of U.S. Market Development

CVRx, Inc., a private medical device company, today announced the appointment of Tom Moore to the newly created, officer position of Vice President, U.S. Market Development.

STAT-Diagnostica Attracts Siemens Venture Capital as a New Investor

Aura Biosciences Secures $8 Million in Additional Funding and Augments Board of Directors and Clinical Advisory Board

The round of financing consisted of expanded funding commitments from its existing investors

TiGenix Appoints Dr. June Almenoff to its Board of Directors